路透纽约6月24日 - CignaCI.N周二起诉百时美施贵宝BMY.N，指控该制药商违反联邦反垄断法，维持对以Pomalyst品牌销售的多发性骨髓瘤特效药的垄断。
该保险公司称，百时美施贵宝及其 Celgene 部门推迟了 Pomalyst 的仿制药进入市场，导致 Cigna 和其他购买者多支付了数亿甚至数十亿美元。
Cigna 向曼哈顿联邦法院提起诉讼。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.